Vaccination from COVID-19 this year will begin in Russia, and then will be carried out in Central Asia. This assumption is made by Katharina Wagner in the German newspaper Frankfurter Allgemeine Zeitung. The article of the German journalist with some abbreviations is published by the online newspaper “Uzbekistan News”.
The article notes that in the global race around the creation of a vaccine against coronavirus, in which Beijing, Washington and the EU participate, Russia does not stand aside and even makes bold predictions about when the vaccine can appear.
At the end of July, a drug for widespread use may appear, said Minister of Health Mikhail Murashko. Other members of the government promised that vaccination would begin in the fall.
An ambitious plan was set in April by Russian President Vladimir Putin. He expects that in September the drug developed in the Russian Federation will be approved for use.
Three different vaccines targeted at social groups at once should go into mass production by the end of the year. According to Russian Deputy Prime Minister Tatyana Golikova, a total of 47 vaccines are being developed by public and private laboratories in Russia.
The subjects receive the so-called vector vaccine, in which the gene material of the new coronavirus is inserted into a harmless virus carrier and injected. It was developed by the N.F. Gamalei Research Institute of Epidemiology and Microbiology in Moscow based on the Ebola vaccine.
The director of the center, Alexander Gunzburg, said on state television that the vaccine he developed “with high probability” would create immunity not for several months, but for two years or more. Such statements seem bold compared to caution prevailing among virologists.
Around the NF Gamalei Research Institute, which reports to the Ministry of Health, there are concentrated influential sponsors who, most likely, expect the vaccine to be successful. Their financial support is also necessary because the state allocates only about 40 million euros for the development of vaccines and test systems.
About the same amount was allocated at the end of April by the Russian Sberbank. According to media reports, the bank also created a company that will undertake to produce a vaccine developed by the NF Gamalei Research Institute.
Also, the Russian Direct Investment Fund (RDIF) is participating in the research project. During the tests, the vaccine shows very good results and is one of the “most promising in the world,” the fund noted. Together with the AFK Sistema concern, which recently acquired the German supermarket chain Real, the foundation also creates a vaccine production site.
“The start of mass production is expected in the fall. Once domestic demand is met, the RDIF plans to begin exporting the vaccine. Potential buyers may be countries associated with Russia, such as Belarus and the countries of Central Asia,” the publication notes.